VERO Cells

VERO cells are widely used in developing vaccines, in the study of viral infections or malaria, and in tumor immunology and immunotherapy studies. VERO cells were derived from the kidney of an African green monkey in the 1960s by a group of Japanese scientists at Chiba University in Japan.
One of the critical characteristics of VERO cells is their rapid growth rate, with a population doubling time of approximately 24 hours. This, combined with their stability and high viral titers, makes them an ideal choice for vaccine production. As a prominent example, a Vero cell-derived vaccine for Japanese encephalitis is widely used and licensed in many countries worldwide.
Vero cells were pivotal in the development of vaccines for a plethora of infectious diseases, including the rubella virus, Ross River virus, herpes simplex virus, measles virus, and poliovirus. Vero cells are renowned for their capacity for virus production, growth, and maintenance under optimized culture conditions, making them an invaluable resource in viral vaccine production. The role of Vero cells extends to the generation of viral vectors, crucial for both vaccine development and tissue engineering applications, and virus isolation.
Different VERO cell lines, such as Vero 76 and the subclone Vero E6, offer unique characteristics suited to various research and production needs. Vero 76 cells are known for their robust growth and are widely used in vaccine production due to their high virus yield capabilities. Vero E6, on the other hand, exhibits specific properties that make it particularly useful for studying certain viruses, including enhanced sensitivity to the Ebola virus and SARS-CoV-2. This subclone’s unique interaction with viruses makes it valuable for viral pathogenesis studies and antiviral drug screening.